ISTH Releases Evidence-Based Clinical Practice Guideline for Hemophilia Treatment USA - English APAC - English USA - English
ncarol.com/10264909

CHAPEL HILL, N.C., June 21, 2024 ~ The International Society on Thrombosis and Haemostasis (ISTH) has recently released a groundbreaking clinical practice guideline for the treatment of congenital hemophilia A and B. This guideline, developed over several years by a multidisciplinary panel of physicians and patient representatives from around the world, utilizes strict GRADE methodology to provide a rigorous and structured decision-making framework for clinicians, healthcare professionals, patients, and their caregivers.

Hemophilia is a rare bleeding disorder caused by deficiencies in blood coagulation factors. It affects hundreds of thousands of individuals worldwide and requires complex management strategies. The objective of this guideline is to offer a comprehensive overview of evidence to help inform treatment decisions.

The panel prioritized key clinical questions and outcomes crucial for both clinicians and patients. The recommendations underwent rigorous analyses, including public commentary, to ensure comprehensiveness, transparency, and inclusivity. The result is a set of 13 recommendations addressing critical aspects of hemophilia A and B care.

More on ncarol.com

• Simpalm Staffing Launches Tax Preparer Staffing for U.S. CPA Firms
• ASSIST Software Wins Volkswagen Challenge for Automated Quality Inspection
• National Literacy and Workforce Readiness Crisis Sparks New Program Launching in Birmingham
• New England Consulting Partners Celebrates 25 Years of Turnaround Management Solutions
• RAS AP Consulting Releases Educational Resource to Help Organizations Prepare for IRS FIRE-to-IRIS Transition

One of the most significant recommendations advocates for prophylactic treatment over episodic interventions for severe and moderately severe hemophilia A and B. This marks a paradigm shift in clinical practice as it emphasizes the importance of preventing bleeds rather than treating them after they occur.

Dr. Suely M. Rezende, Chair of the ISTH Hemophilia Guideline Panel, stated that "with hemophilia management being complex, our guideline provides clarity, guiding treatment decisions with evidence-based insight while highlighting the importance of considering individual risks, values, and preferences."

To provide further guidance on the interpretation and implementation of the guideline, commentaries have been published alongside it by preeminent experts in the field. These commentaries also address challenges for clinical practice and policy related to hemophilia treatment.

More on ncarol.com

• Roots, Rhythm & Joy Invites Neighbors to Find Community Through Music
• Former Goddard Enterprises Managing Director Anthony Ali Joins STS Capital Partners as Managing Director and Partner
• Disney Streamer Network Establishes Creator Code of Conduct
• Heritage at Manalapan Announces Limited-Time Mortgage Rate Buydown on Select Quick Move-In Homes
• Good Organics Now at Pop Up Grocer NYC With October 30 Sampling Event

The new guideline also addresses important gaps in scientific data and identifies critical research priorities. As new treatments become available in the ever-evolving landscape of hemophilia care, future updates to the guideline are expected to encompass these advancements.

The ISTH remains committed to advancing hemophilia research and improving the lives of people with hemophilia worldwide. By continuously updating and complementing this guideline, they aim to drive innovation and enhance outcomes for individuals living with this rare disease.

For more information and to access the full guideline and accompanying commentaries, please visit https://www.isth.org/page/hemophiliaguideline. This comprehensive resource provides valuable insights into the evolving hemophilia treatment landscape and emphasizes the importance of patient involvement and shared decision-making in treatment decisions.

---

Show All News | Disclaimer | Report Violation